Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients

Traders Union
All News
Companies
Eyepoint advances Phase 3 DME therapy

Top Stories

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Mikhail Vnuchkov

18.03.2026

Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients — Eyepoint advances Phase 3 DME therapy

Eyepoint Pharmaceuticals is pushing forward with its pivotal Phase 3 program aimed at addressing diabetic macular edema (DME), following ongoing challenges with current anti-VEGF therapies that leave many patients facing persistent vision loss.

The company is targeting the development of more durable treatments that also address inflammation, seeking to fill the therapeutic gap left by existing options. More information about the Phase 3 program is available through the company’s official channels.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

As Eyepoint Pharmaceuticals advances its Phase 3 efforts in diabetic macular edema, these developments build on the company’s broader strategy to strengthen its market position, following significant leadership appointments such as Michael Campbell’s role as chief commercial officer to enhance product launches. Further insight into this strategic direction can be found in the context of Eyepoint’s decision to appoint Campbell to boost product launches.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

How to build wealth from scratch in 3 practical steps

By Johnathan Maverick
10 hours ago

How to build wealth from scratch in 3 practical steps

Editors' Picks

Kospi Index crash: Why South Korean market fell alongside AI stocks

By Eugene Komchuk
13 hours ago

Kospi Index crash: Why South Korean market fell alongside AI stocks

Editors' Picks

Bitcoin or Ferrari: Which investment is better?

By Mira Kyivska
Yesterday

Bitcoin or Ferrari: Which investment is better?

Editors' Picks

All Editors' Top Picks

Latest Eyepoint News

Eyepoint Pharmaceuticals advances new therapies for serious retinal diseases in June campaign

By Andrey Mastykin
04.06.2026

Eyepoint Pharmaceuticals advances new therapies for serious retinal diseases in June campaign

Companies

Eyepoint Pharmaceuticals to participate in Jefferies Global Healthcare event webcast

By Parshwa Turakhiya
02.06.2026

Eyepoint Pharmaceuticals to participate in Jefferies Global Healthcare event webcast

Companies

Eyepoint Pharmaceuticals CEO featured for advances in OCT retina imaging tool

By Igor Krasulya
29.05.2026

Eyepoint Pharmaceuticals CEO featured for advances in OCT retina imaging tool

Companies

All Eyepoint News

Johnathan Maverick
10 hours ago

How to build wealth from scratch in 3 practical steps

Eugene Komchuk
13 hours ago

Kospi Index crash: Why South Korean market fell alongside AI stocks

Mira Kyivska
Yesterday

Bitcoin or Ferrari: Which investment is better?

Mira Kyivska
06.06.2026

Strategy sells Bitcoin: Small sale tests market confidence

Mikhail Vnuchkov
05.06.2026

Ledger vs. Trezor: Search for ideal crypto wallet

Hanna Syniavska
27 min ago

Mason Versluis: Reasons for buying XRP despite weak price action

Ivan Andriyenko
28 min ago

Jurrien Timmer: Strong U.S. jobs data and Iran conflict keep inflation elevated

Elena Nikulina
33 min ago

Nasdaq broke Friday low by following week in 19 of 21 cases, Brian Sozzi notes

Anastasiia Chabaniuk
58 min ago

World trade grew more open while U.S. and China set records, Richard Baldwin notes

Mikhail Vnuchkov
1 hour ago

Hedonic models outside shelter and apparel slightly impact CPI, Jeremy Horpedahl notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Eugene Komchuk
6 hours ago

Sam Bankman-Fried formally seeks pardon from Trump

Sam Bankman-Fried formally seeks pardon from Trump

Ivan Andriyenko
9 hours ago

Hayes dumps WLD days after Maelstrom's bullish call

Hayes dumps WLD days after Maelstrom's bullish call

Hanna Syniavska
11 hours ago

Powell warns Trump pressure on Fed could threaten markets

Powell warns Trump pressure on Fed could threaten markets

Igor Krasulya
13 hours ago

Nvidia bets on South Korea in AI infrastructure race

Nvidia bets on South Korea in AI infrastructure race

Olga Shendetskaya
14 hours ago

Oil rises above $97 after new Israel-Iran exchange of strikes

Oil rises above $97 after new Israel-Iran exchange of strikes

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Alphabet decline intensifies amid record AI investment

Anton Kharitonov
Now

Microsoft declines amid AI expectation reset, but fundamentals remain strong

Dmytro Kharkov
Now

Snowflake tests post-earnings breakout as AI rally faces first challenge

Anton Kharitonov
Now

Apple under pressure as investor skepticism grows

Dmytro Kharkov
Now

Nvidia tests key support as Jensen Huang calls AI sell-off a buying opportunity

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.